UTHR · Nasdaq · CIK 0001082554
UNITED THERAPEUTICS Corp
UNITED THERAPEUTICS Corp’s most recent SEC filing in our snapshot is a Form 4 filed on Oct 27, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $3.2B and net income of $1.3B, according to its XBRL data on EDGAR. Its EDGAR record lists 322 Form 4 insider filings from the 12 months before our last refresh.
SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.
Company overview
- Legal name (as filed)
- UNITED THERAPEUTICS Corp
- Ticker
- UTHR
- SEC Central Index Key (CIK)
- 0001082554
- Industry (SIC)
- Pharmaceutical Preparations (code 2834)
- Business address
- SILVER SPRING, MD
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- SEC filer category
- Large accelerated filer
- Position in SEC ticker list
- #518 of the 3,000 companies we track
Five-year financial highlights
Full-year figures from UNITED THERAPEUTICS Corp’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.
| Item | FY2021 ended Dec 31, 2021 | FY2022 ended Dec 31, 2022 | FY2023 ended Dec 31, 2023 | FY2024 ended Dec 31, 2024 | FY2025 ended Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.7B | $1.9B | $2.3B | $2.9B | $3.2B |
| Net income | $475.8M | $727.3M | $984.8M | $1.2B | $1.3B |
| Diluted EPS | $10.06 | $15.00 | $19.81 | $24.64 | $27.86 |
| Total assets | $5.2B | $6.0B | $7.2B | $7.4B | $7.9B |
| Cash and equivalents | $894.8M | $961.2M | $1.2B | $1.7B | $1.6B |
XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.
How to read these numbers
Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.
Advertisement
Latest key reports
The most recent filing of each major report type, even if it falls outside the 40 newest filings below.
| Filed | Form | What it is | Original |
|---|---|---|---|
| Feb 25, 2026 | 10-K | Annual report· period Dec 31, 2025 | Document · Index |
| Aug 5, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Oct 22, 2026 | 8-K | Other events· period Oct 21, 2026 | Document · Index |
| Apr 29, 2026 | DEF 14A | DEFINITIVE PROXY STATEMENT· period Jun 26, 2026 | Document · Index |
Recent SEC filings
The 40 newest documents filed by or about UNITED THERAPEUTICS Corp, by form type:
| Filed | Form | What it is | Original |
|---|---|---|---|
| Oct 27, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 26, 2026 | Document · Index |
| Oct 26, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 23, 2026 | Document · Index |
| Oct 23, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 22, 2026 | Document · Index |
| Oct 22, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 21, 2026 | Document · Index |
| Oct 22, 2026 | 8-K | Other events· period Oct 21, 2026 | Document · Index |
| Oct 21, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 20, 2026 | Document · Index |
| Oct 20, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 19, 2026 | Document · Index |
| Oct 19, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 16, 2026 | Document · Index |
| Oct 16, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 15, 2026 | Document · Index |
| Oct 16, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 15, 2026 | Document · Index |
| Oct 15, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Oct 15, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 14, 2026 | Document · Index |
| Oct 14, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 13, 2026 | Document · Index |
| Oct 14, 2026 | 8-K | Other events· period Oct 13, 2026 | Document · Index |
| Oct 13, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 12, 2026 | Document · Index |
| Oct 13, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 9, 2026 | Document · Index |
| Oct 9, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 8, 2026 | Document · Index |
| Oct 8, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 7, 2026 | Document · Index |
| Oct 7, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 6, 2026 | Document · Index |
| Oct 6, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 5, 2026 | Document · Index |
| Oct 5, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 2, 2026 | Document · Index |
| Oct 2, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 1, 2026 | Document · Index |
| Oct 1, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Oct 1, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Oct 1, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 1, 2026 | Document · Index |
| Oct 1, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 30, 2026 | Document · Index |
| Oct 1, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 30, 2026 | Document · Index |
| Sep 30, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 29, 2026 | Document · Index |
| Sep 29, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 28, 2026 | Document · Index |
| Sep 28, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 25, 2026 | Document · Index |
| Sep 25, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 24, 2026 | Document · Index |
| Sep 24, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 23, 2026 | Document · Index |
| Sep 23, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 22, 2026 | Document · Index |
| Sep 22, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 21, 2026 | Document · Index |
| Sep 21, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 18, 2026 | Document · Index |
| Sep 18, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 17, 2026 | Document · Index |
| Sep 18, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 17, 2026 | Document · Index |
| Sep 17, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Sep 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 16, 2026 | Document · Index |
| Sep 16, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 15, 2026 | Document · Index |
Insider filing activity
322 Form 4 filings appear in UNITED THERAPEUTICS Corp’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.
Advertisement
Other companies in Pharmaceutical Preparations
- LLY ELI LILLY & Co
- JNJ JOHNSON & JOHNSON
- ABBV AbbVie Inc.
- MRK Merck & Co., Inc.
- NVS NOVARTIS AG
- AZN ASTRAZENECA PLC
- ABT ABBOTT LABORATORIES
- NVO NOVO NORDISK A S
All 194 companies in Pharmaceutical Preparations· Companies headquartered in Maryland
On Amazon
Popular tools for investors
As an Amazon Associate I earn from qualifying purchases.
Source
- U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001082554 and XBRL company facts. UNITED THERAPEUTICS Corp on EDGAR.
- Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.
Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.
Advertisement